Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019Klinisches Register des „Europäischen Mantelzelllymphom Netzwerk (EMCL)“. Erfassung von Patienten mit neu diag-nostiziertem oder rezidiviertem Mantelzelllymphom
Clinical Studies - Dec 20, 2019 - Dec 20, 2025
Scheduled
Project leader: Fehr Martin
HOVON 150
Dec 18, 2019IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...
Clinical Studies - Dec 18, 2019 - Jan 31, 2027
Ongoing
Project leader: Schittenhelm Marcus
A Phase 1b/2 Multicenter, Open-label, Expansion Study to As-sess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Dec 5, 2019Bispezifische, T-Zell-aktivierende Antikörper (BITE) sind eine vielversprechende Option, um eine zellvermittelte Immuntherapie von Tumoren zu erreichen. In der vorlie-genden Studie wird die Wirksamkeit und Sicherheit eines gegen das Oberflächenantige...
Clinical Studies - Dec 5, 2019 - Dec 23, 2020
Automatically Closed
Project leader: Driessen Christoph
Members: Silzle Tobias
SAKK 66/18: A phase Ib trial of copanlisib in combina-tion with venetoclax in patients with relapsed or refrac-tory lymphoma
Sep 13, 2019A significant number of patients with non-Hodgkin lym-phoma (NHL) are not cured with available treatments and will eventually relapse. Those patients might not be able to tolerate more bone marrow toxicity, limiting their treatment options. Preclinic...
Clinical Studies - Sep 13, 2019 - Dec 31, 2022
Automatically Closed
Project leader: Hess Dagmar
A phase I/Ib, open-label, multi-center dose escalation study of NIS793 in combination with PDR001 in adult patients with advanced malignancies (CNIS793X2101)
Sep 9, 2019This is a first-in-human (FIH), open label, phase I/Ib, multi-center study which consists of: - a dose escalation part of NIS793 as single agent and in combination with PDR001. Patients treated with NIS793 single agent will switch to NIS793 in combin...
Clinical Studies - Sep 9, 2019 - Jul 1, 2021
Automatically Closed
Project leader: Jörger Markus
SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts
Jul 24, 2019Main objective: To investigate efficacy of a stage-adapted tratment regimen in stage IIA/B seminoma based on the preliminary experience gained in SAKK 01/10. The Goal is to further safely de-escalate Treatment while maintaining / enhancing efficacy.
Clinical Studies - Jul 24, 2019 - Jul 24, 2030
Ongoing
Project leader: Putora Paul Martin
Members: Plasswilm Ludwig, Panje Cédric, Omlin Aurelius, Rothermundt Christian, Aeppli Stefanie
SAKK 21/18 Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A mul-ticenter, randomized phase III trial
Jun 25, 2019Breast cancer is the most frequent malignancy in women and the leading cause of cancer mortality in most countries in Europe. Metastatic breast cancer remains an incurable disease with a median overall survival (OS) of 2–4 years and a 5 year surviv...
Clinical Studies - Jun 25, 2019 - Dec 31, 2026
Ongoing
Project leader: Hasler-Strub Ursula
A multicentre randomised phase III trial comparing atezolizumab
Jun 20, 2019Evaluation einer Immuntherapie in der ersten Therapielinie in Kombination mit einer Standard Chemo-/Avastintherapie bei Patienten mit malignem Mesotheliom
Clinical Studies - Jun 20, 2019 - Jul 4, 2025
Ongoing
Project leader: Früh Martin
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbes-serung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Dec 17, 2023
Scheduled
Project leader: Jörger Markus
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Aug 30, 2023
Scheduled
Project leader: Jörger Markus
ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Dec 31, 2023
Scheduled
Project leader: Jörger Markus
Peace-4
Apr 26, 2019Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is ab...
Clinical Studies - Apr 26, 2019 - May 6, 2027
Scheduled
Project leader: Omlin Aurelius
A Phase 3 Study Comparing Daratumumab, VELCADE (borte-zomib), Lenalidomide, and Dexamethasone (D-VRD) vs VELCADE, Lenalidomide, and Dexamethasone (VRD) in Sub-jects with Previously Untreated Multiple Myeloma who are Eligi-ble for High-dose Therapy
Apr 18, 2019This is a randomized, open-label, multicenter study evalu-ating subjects with newly diagnosed multiple myeloma who are deemed eligible for high-dose therapy. Approximately 690 subjects will be stratified by International Staging Sys-tem (ISS) Stage I...
Clinical Studies - Apr 18, 2019 - Dec 1, 2029
Ongoing
Project leader: Silzle Tobias
Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Apr 15, 2019Kombination von Nivolumab mit dem anti-IL8 monoklona-len Antikörper BMS-986253 in PatientInnen mit selektierten fortgeschrittenen soliden Malignomen und erhöhten IL-8 Blutspiegeln.
Clinical Studies - Apr 15, 2019 - Dec 31, 2020
Automatically Closed
Project leader: Jörger Markus
A phase III trial of marizomib in combination with standard
Jan 14, 2019Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1)
Clinical Studies - Jan 14, 2019 - Jun 20, 2019
Automatically Closed
Project leader: Hess Dagmar
A phase III trial of marizomib in combination with standard
Dec 13, 2018Marizomib in Glioblastoma
Clinical Studies - Dec 13, 2018 - Nov 13, 2021
Automatically Closed
Project leader: Hundsberger Thomas
MK-3475-495 KeyImPaCT
Dec 12, 2018Open-label randomisierte Phase II Studie, welche in der Erstlinientherapie bei Patienten mit metastasiertem NSCLC die Kombination von Pembrolizumab mit entweder MK-4280 oder lenvatinib untersucht. Ausgenommen sind Patienten für die eine zielgericht...
Clinical Studies - Dec 12, 2018 - Dec 19, 2020
Automatically Closed
Project leader: Schmid Sabine
IBCSG 55-17 “Touch” Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer
Dec 4, 2018CDK4/6-Inhibitoren bringen enorme Verbesserungen bei der Behandlung von Patienten mit fortgeschrittenen, HR+ (Hormonrezeptor positiv)/HER2- (human epidermal growth factor receptor 2 negativ) BC (Brustkrebserkrankungen). Palbociclib und andere CDK4/6-...
Clinical Studies - Dec 4, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Weder Patrik
Phase 1 Studie mit dem neuen liposomalen Doxorubicin TLD-1 in Patienten mit fortgeschrittenen soliden Tumoren
Oct 26, 2018In dieser Studie wird zum ersten Mal die Sicherheit und Wirksamkeit eines neuen Medikaments (Talidox) bei Menschen untersucht. Bei dem neuen Medikament handelt es sich um einen bekannten Wirkstoff, das Chemotherapeutikum Doxorubicin, welches in einer...
Clinical Studies - Oct 26, 2018 - Dec 31, 2026
Ongoing
Project leader: Hess Dagmar
Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positve, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
Oct 23, 2018Lung cancer is the leading cause of cancer deaths. An estimated 30 to 40% of patients diagnosed with NSCLC have a poor PS defined as a score of 2 or higher on the ECOG scale. PS 2 patients are often underrepresented in clinical trials despite represe...
Clinical Studies - Oct 23, 2018 - Nov 23, 2021
Automatically Closed
Project leader: Früh Martin